We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Develops, manufactures and markets rapid diagnostic tests at the point-ofcare (POC) that focus on infectious diseases... read more Featured Products: More products

Download Mobile App

Quidel Receives FDA Emergency Use Authorization for QuickVue SARS Rapid Antigen Test for COVID-19 Diagnosis

By LabMedica International staff writers
Posted on 22 Dec 2020
Print article
Image: QuickVue SARS Antigen test (Photo courtesy of Quidel Corporation)
Image: QuickVue SARS Antigen test (Photo courtesy of Quidel Corporation)
Quidel Corporation (San Diego, CA, USA) has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) to market its QuickVue SARS Antigen test.

The point-of-care assay is intended for the rapid, qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in anterior nares (NS) swab specimens directly from individuals who are suspected of COVID-19 by their healthcare provider within the first five days of the onset of symptoms.
Gold Supplier
COVID-19 Antibody Rapid Detection Kit
COVID-19 Antibody Rapid Detection Kit
COVID-19 Positive Control
STAT-NAT COVID-19 Positive Control
Visit expo >

Quidel’s new QuickVue SARS Antigen test requires no supplemental instrumentation and is visually read. It offers excellent performance for the detection of SARS-CoV-2 (96.6% PPA versus PCR and 99.3% NPA versus PCR) in anterior nares swab samples, yielding results in just 10 minutes, thereby providing quick, reliable results to patients, their families and healthcare workers alike.

“We are proud to introduce yet another powerful diagnostic tool to aid the fight against COVID-19,” said Douglas Bryant, president and CEO of Quidel Corporation. “The QuickVue rapid antigen test for coronavirus leverages our proven QuickVue visually read diagnostic platform for influenza A+B to further democratize access to affordable and highly accurate COVID-19 testing across a diverse range of medical and point-of-care locations.”

“The flexibility of QuickVue for meeting the urgent testing needs of everyone from school systems to rural areas and even locations without electricity gives us the opportunity to do enormous good in communities across our nation and the world,” Mr. Bryant noted. “We will scale immediately to supply the more than 30,000 QuickVue professional market customers we serve today and look forward to extending the benefits of this technology as broadly and rapidly as possible in the months and years ahead.”

Print article


Molecular Diagnostics

view channel
Image: Histopathology of neurofibrillary tangles in the brain of a patient with Alzheimer`s disease (Bielschowski silver stain) (Photo courtesy of Dimitri P. Agamanolis, MD).

Alzheimer's Disease Subtypes Proposed from Brain Gene Expression Profiles

Alzheimer’s disease (AD) is the most common form of dementia in the elderly, estimated to affect more than 5.8 million individuals in the USA and more than 50 million worldwide, with almost half of individuals... Read more


view channel

Thermo Fisher Acquires Point-of-Care Molecular Diagnostics Provider Mesa Biotech

Thermo Fisher Scientific Inc. (Waltham, MA, USA) has entered into a definitive agreement to acquire Mesa Biotech (San Diego, CA, USA), a privately held molecular diagnostic company, for approximately USD... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.